Abbott Laboratories 8-K

Executive pay

Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

Filed 2026-11-13 17:59 ET

Summary

Executive change-in-control agreements extended. On 11/11/2026, Abbott extended the agreements for its named executive officers other than Chairman and CEO Robert B. Ford through 12/31/2028; Ford’s agreement expires on 12/31/2026.

Was this summary useful?

The summary is written by an AI model reading the filing.

Model 005 · prompt v192 · 2026-11-16 15:37:01Z

Feedback